Sangamo Therapeutics (NASDAQ:SGMO) Cut to "Sell" at Wall Street Zen

Wall Street Zen lowered shares of Sangamo Therapeutics (NASDAQ:SGMO - Free Report) from a hold rating to a sell rating in a research note published on Friday morning.

SGMO has been the subject of several other reports. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $2.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. Barclays dropped their price target on Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. Finally, HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a report on Monday, April 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $4.50.

Sangamo Therapeutics Price Performance

SGMO traded down $0.01 during midday trading on Friday, hitting $0.45. 4,185,721 shares of the company's stock traded hands, compared to its average volume of 8,771,199. The company has a market cap of $105.16 million, a PE ratio of -0.60 and a beta of 1.46. The stock's fifty day simple moving average is $0.65 and its 200-day simple moving average is $1.19. Sangamo Therapeutics has a one year low of $0.30 and a one year high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The company had revenue of $6.44 million during the quarter, compared to analyst estimates of $7.90 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. On average, research analysts expect that Sangamo Therapeutics will post -0.46 EPS for the current year.

Institutional Trading of Sangamo Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its position in shares of Sangamo Therapeutics by 679.5% during the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 21,793 shares during the period. SBI Securities Co. Ltd. bought a new position in shares of Sangamo Therapeutics during the 4th quarter valued at about $28,000. Geode Capital Management LLC lifted its holdings in shares of Sangamo Therapeutics by 3.4% during the 4th quarter. Geode Capital Management LLC now owns 2,211,849 shares of the biopharmaceutical company's stock valued at $2,257,000 after purchasing an additional 73,540 shares in the last quarter. Lazard Asset Management LLC bought a new position in shares of Sangamo Therapeutics during the 4th quarter valued at about $47,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Sangamo Therapeutics during the 4th quarter valued at about $353,000. 56.93% of the stock is currently owned by institutional investors and hedge funds.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.